Developed novel chemistry that selectively delivers pharmaceuticals to a specific tissue
Mesentech has developed a bone-targeting prodrug MES1007 that avoids systemic exposure and side effects by specifically delivering drugs to the bone. Over the years, Mesentech founders have developed unique partnership with Merck, Cure Duchenne, and Charles H. Hood Foundation.
Neuroimaging AI software solutions that transform outcomes for research, clinical trials, and care delivery
Working at the frontier of vascular and musculoskeletal tissue regeneration